16 July 2023: Clinical Research
A Nomogram for Identifying HR+/Her2− Breast Cancer Patients with Positive Sentinel Lymph Nodes and Omitted Axillary Lymph Node Dissection Who Need Abemaciclib Therapy
Hanzhao Yang CDE , Yadong Sun BCD , Peili Wang BD , Jianghua Qiao BC , Lianfang Li B , Zhenduo Lu B , Xianfu Sun B , Chongjian Zhang B , Xiuchun Chen B , Min Yan B , Shude Cui B , Chengzheng Wang ADF , Zhenzhen Liu AE*DOI: 10.12659/MSM.940124
Med Sci Monit 2023; 29:e940124
Table 1 Characteristics of HR+/HER2− patients.
| Characteristics | Patients (n=444) |
|---|---|
| Age, Median (min, max), years | 50 (26–80) |
| 215 (48.4%) | |
| ≥50, no. (%) | 229 (51.6%) |
| BMI | 24.4 (22.3–26.1) |
| Menopausal status, no. (%) | |
| Premenopausal | 254 (57.2%) |
| Postmenopausal | 190 (42.8%) |
| Multifocality, no. (%) | |
| Absent | 394 (88.7%) |
| Present | 50 (11.3%) |
| Clinical tumor stage, no. (%) | |
| 1 | 274 (61.7%) |
| 2 | 170 (38.3%) |
| Tumor size, Median (min, max), cm | 1.9 (0.2–5.0) |
| US-ALN, no. (%) | |
| Normal | 298 (67.1%) |
| Abnormal | 146 (32.9%) |
| Mammographic calcifications, no. (%) | |
| Absent | 365 (82.2%) |
| Present | 79 (17.8%) |
| Surgery, no. (%) | |
| Mastectomy | 350 (78.8%) |
| Breast-conserving | 94 (21.2%) |
| Tumor type, no. (%) | |
| Ductal | 425 (95.7%) |
| Lobular | 15 (3.4%) |
| Others | 4 (0.9%) |
| Histological grade, no. (%) | |
| I | 7 (1.6%) |
| II | 397 (89.4%) |
| Missing | 40 (9.0%) |
| 1 positive SLNs removed. total, no. (%) | 318 (71.6%) |
| 0 positive non-SLNs, no | 166 |
| 1 positive non-SLNs, no | 95 |
| 2 positive non-SLNs, no | 27 |
| ≥3 positive non-SLNs, no | 30 |
| 2 positive SLNs removed. total, no. (%) | 126 (28.4%) |
| 0 positive non-SLNs, no | 62 |
| 1 positive non-SLNs, no | 18 |
| 2 positive non-SLNs, no | 22 |
| ≥3 positive non-SLNs, no | 24 |
| pN stage, no. (%) | |
| 1 | 367 (82.7%) |
| 2–3 | 77 (17.3%) |
| LVI, no. (%) | |
| Absent | 348 (78.4%) |
| Present | 96 (21.6%) |
| Progesterone receptor, no. (%) | |
| Negative | 33 (7.4%) |
| Positive | 411 (92.6%) |
| HER2 expression, no. (%) | |
| 0 | 64 (14.4%) |
| 1+ | 137 (30.9%) |
| 2+ | 243 (54.7%) |
| BMI – body mass index; US-ALN – ultrasound finding axillary lymph node; SLN – sentinel lymph node; LVI – lymphovascular invasion. | |